↓ Skip to main content

Targeting TLR-4 with a novel pharmaceutical grade plant derived agonist, Immunomax®, as a therapeutic strategy for metastatic breast cancer

Overview of attention for article published in Journal of Translational Medicine, November 2014
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (94th percentile)
  • High Attention Score compared to outputs of the same age and source (96th percentile)

Mentioned by

news
4 news outlets
twitter
4 tweeters
peer_reviews
1 peer review site
facebook
1 Facebook page

Citations

dimensions_citation
23 Dimensions

Readers on

mendeley
56 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Targeting TLR-4 with a novel pharmaceutical grade plant derived agonist, Immunomax®, as a therapeutic strategy for metastatic breast cancer
Published in
Journal of Translational Medicine, November 2014
DOI 10.1186/s12967-014-0322-y
Pubmed ID
Authors

Anahit Ghochikyan, Alexey Pichugin, Alexander Bagaev, Arpine Davtyan, Armine Hovakimyan, Amir Tukhvatulin, Hayk Davtyan, Dmitry Shcheblyakov, Denis Logunov, Marina Chulkina, Anastasia Savilova, Dmitry Trofimov, Edward L Nelson, Michael G Agadjanyan, Ravshan I Ataullakhanov

Abstract

BackgroundPreviously we demonstrated that the resection of primary 4 T1 tumors only slightly prolongs mouse survival, but importantly, creates a ¿window of opportunity¿ with attenuated suppressor cell and increased activated T cell populations. This suggests that additional activation of the immune system by immunostimulatory agents during this period may enhance anti-tumor immunity and potentially eradicate micro-metastatic disease in this stringent model.We hypothesized that the immunostimulator Immunomax®, which is comprised of a plant-derived polysaccharide, is non-toxic in humans and stimulates immune defense during the infectious diseases treatment, may have also anti-tumor activity and be beneficial in the adjuvant setting when endogenous anti-tumor responses are present and during the ¿window of opportunity¿ in post-resection metastatic breast cancer model. Here we provide the initial report that Immunomax® demonstrates the capacity to eliminate micro-metastatic disease in the post-resection, 4 T1 mouse model of breast cancer.MethodsThe efficacy of Immunomax® was evaluated by analyzing survival rate and the number of spontaneous clonogenic tumor cells in the lung homogenates of mice. The frequencies of activated NK, CD4+ and CD8+ cells as well as myeloid-derived suppressor cells and Treg cells were evaluated using flow cytometry. Highly purified mouse and human dendritic and NK cells were sorted and the effect of Immunomax® on activation status of these cells was assessed by flow cytometry. The property of Immunomax® as TLR-4 agonist was determined by NF-¿B/SEAP reporter gene assay, WB, RT-PCR.Results Immunomax® injections significantly prolonged overall survival and cured 31% of mice. This immunostimulator activates DCs via the TLR-4, which in turn stimulates tumoricidal NK cells and in vitro, completely inhibits growth of 4 T1 cells. Incubation of PBMC from healthy donors with Immunomax® activates NK cells via activation of plasmacytoid DC leading significantly higher efficacy in killing of human NK-target cells K562 compared with non-treated cells.ConclusionThis is the first demonstration that Immunomax® is a TLR-4 agonist and the first report of a documented role for this pharmaceutical grade immunostimulator in augmenting anti-tumor activity, suggesting that incorporation of Immunomax® into developing breast cancer therapeutic strategies may be beneficial and with less potential toxicity than checkpoint inhibitors.

Twitter Demographics

The data shown below were collected from the profiles of 4 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 56 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Poland 1 2%
Unknown 55 98%

Demographic breakdown

Readers by professional status Count As %
Researcher 12 21%
Student > Ph. D. Student 11 20%
Student > Bachelor 9 16%
Student > Postgraduate 4 7%
Other 3 5%
Other 6 11%
Unknown 11 20%
Readers by discipline Count As %
Medicine and Dentistry 15 27%
Biochemistry, Genetics and Molecular Biology 8 14%
Agricultural and Biological Sciences 8 14%
Immunology and Microbiology 7 13%
Chemistry 3 5%
Other 4 7%
Unknown 11 20%

Attention Score in Context

This research output has an Altmetric Attention Score of 24. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 January 2018.
All research outputs
#1,206,184
of 21,326,488 outputs
Outputs from Journal of Translational Medicine
#208
of 3,676 outputs
Outputs of similar age
#19,367
of 345,828 outputs
Outputs of similar age from Journal of Translational Medicine
#11
of 328 outputs
Altmetric has tracked 21,326,488 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,676 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.1. This one has done particularly well, scoring higher than 94% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 345,828 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 94% of its contemporaries.
We're also able to compare this research output to 328 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 96% of its contemporaries.